8-K: Avalo Therapeutics Announces Second Quarter 2024 Financial Results and Business Updates, Expects First Patient Enrollment in Phase 2 LOTUS Trial

Avalo Therapeutics reported its second quarter 2024 financial results, highlighted by a $93.4 million cash position and the expected initiation of the Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa in the second half of 2024.

Summary

• Avalo Therapeutics announced its financial results for the second quarter of 2024, reporting a net loss of $22.8 million for the six months ended June 30, 2024, which is an increase of $4.7 million compared to the same period in 2023.
• The company's operating expenses increased by $25.3 million, primarily due to a $27.6 million expense related to acquired in-process research and development from the AlmataBio acquisition.
• Avalo's cash and cash equivalents totaled $93.4 million as of June 30, 2024, which is expected to fund operations into 2027.
• The company expects to enroll the first patient in its Phase 2 LOTUS Trial for AVTX-009 in hidradenitis suppurativa in the second half of 2024.
• Avalo appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal Officer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the strong cash position and progress in clinical trials, but tempered by the increased net loss and operating expenses.

Positives

• Avalo has a strong cash position of $93.4 million, providing a cash runway into 2027.
• The IND for AVTX-009 in hidradenitis suppurativa is active, allowing the Phase 2 LOTUS Trial to proceed.
• The company is on track to enroll the first patient in the Phase 2 LOTUS Trial in the second half of 2024.
• The appointments of Dr. Mittie Doyle and Paul Varki to key leadership roles are expected to benefit the company.

Negatives

• The company experienced a net loss of $22.8 million for the six months ended June 30, 2024, which is an increase of $4.7 million compared to the same period in 2023.
• Operating expenses increased significantly due to the acquisition of AlmataBio, Inc., including a $27.6 million in-process research and development expense.

Risks

• The company's future success is dependent on the successful outcome of the Phase 2 LOTUS Trial.
• The company's financial performance is subject to the risks associated with drug development, including regulatory approvals and clinical trial outcomes.
• The company's operating expenses are expected to remain high due to ongoing research and development activities.

Future Outlook

Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial in the second half of 2024 and plans to develop AVTX-009 in at least one other chronic inflammatory indication. The company's current cash is expected to fund operations into 2027.

Management Comments

• Dr. Garry Neil, Chief Executive Officer and Chairman of the Board, stated that the team has made outstanding progress toward initiating the Phase 2 LOTUS Trial.
• Dr. Neil also noted that the company is immediately benefiting from the addition of Mittie and Paul to the leadership team.

Industry Context

The development of AVTX-009 targets the inflammatory disease market, specifically hidradenitis suppurativa, which has limited treatment options. The company's focus on IL-1 inhibition aligns with the industry's interest in targeting key drivers of inflammation.

Comparison to Industry Standards

• Avalo's cash position of $93.4 million is relatively strong for a clinical-stage biotech company, providing a runway into 2027, which is longer than many peers.
• The company's focus on hidradenitis suppurativa is in line with the industry's growing interest in addressing unmet needs in dermatology and inflammatory diseases, similar to companies like AbbVie and Novartis who have also invested in this area.
• The increase in operating expenses due to the acquisition of AlmataBio is typical for companies expanding their pipeline through acquisitions, similar to other biotech companies that have acquired assets to bolster their development programs.
• The Phase 2 LOTUS trial is a key milestone for Avalo, and its progress will be closely watched by investors and competitors in the space, similar to other companies with Phase 2 assets in development.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the clinical trials.
• Employees will be impacted by the company's growth and the addition of new leadership.
• Patients with hidradenitis suppurativa may benefit from the development of AVTX-009.

Next Steps

• Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial in the second half of 2024.
• The company plans to develop AVTX-009 in at least one other chronic inflammatory indication.
• Avalo will continue to evaluate and announce a second indication for AVTX-009 in the second half of the year.

Key Dates

Keywords

AVTX-009, hidradenitis suppurativa, Phase 2 LOTUS Trial, monoclonal antibody, inflammatory diseases, clinical trial, biotechnology, financial results, cash runway, net loss